Jiangsu Recbio Technology Co (2179.HK) Stock Price

Jiangsu Recbio Technology Co Price

HKEX·CLOSED
3.40
​
Market closed

Over the last 5 years Jiangsu Recbio Technology Co grew revenue by 53.4% annually, reaching 14.43 M CNY. For Jiangsu Recbio Technology Co, the net margin of -4,796.4% is up versus -10,607.5% a few years ago. The consensus 12-month price target for Jiangsu Recbio Technology Co is 11.30 CNY, about 231.9% above where the stock trades today. Of 9 analysts, 0 rate the stock a buy — an overall Sell consensus.

Jiangsu Recbio Technology Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jiangsu Recbio Technology Co business model & stock analysis

Jiangsu Recbio Technology Co., Ltd. generates revenue through the research and development of vaccines, focusing on clinical-stage and pre-clinical-stage products. The company develops recombinant HPV 9-valent vaccine REC603, recombinant HPV 9-valent vaccines REC601 and REC602, recombinant HPV quadrivalent vaccine REC604a, and recombinant HPV 9-valent vaccine REC604b, alongside Covid-19 vaccine development. Its primary market is the domestic Chinese market, where it distributes these vaccines to healthcare providers and government health programs. The firm's product portfolio includes HPV vaccine pipelines such as REC603, REC601, REC602, REC604a, and REC604b, all targeting cervical cancer prevention. These vaccines are developed for the domestic market, with no mention of international distribution. The company's revenue streams are derived from the sale of these vaccines once they reach commercialization, supported by its 434 full-time employees in research and development. Jiangsu Recbio Technology operates with a focus on vaccine innovation, leveraging its clinical-stage and pre-clinical-stage pipelines to address unmet medical needs. The company's domestic market strategy ensures that its products are distributed through established healthcare channels within China, aligning with the country's public health initiatives and vaccine procurement programs.

Frequently asked questions about Jiangsu Recbio Technology Co

Analysts currently set an average price target of 11.30 CNY for the Jiangsu Recbio Technology Co stock (median: 11.30 CNY), implying +231.9 % versus the latest price. The consensus is based on 9 analyst ratings.

9 analysts currently rate the Jiangsu Recbio Technology Co stock: 0 recommend buying, 3 holding and 6 selling. For 2026, analysts expect Jiangsu Recbio Technology Co to generate revenue of 11.08 M CNY and earnings per share of -0.73 CNY.

Converted at the current exchange rate, the Jiangsu Recbio Technology Co share trades at 0.46 EUR (3.40 CNY).

The Jiangsu Recbio Technology Co share (2179.HK) is listed on 1 stock exchanges, including: Hongkong (HKEX) (2179.HK).

The expected revenue of Jiangsu Recbio Technology Co is 11.08 M CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Jiangsu Recbio Technology Co is -452.28 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Jiangsu Recbio Technology Co is currently -4.66. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Jiangsu Recbio Technology Co stock.

The price-to-sales ratio (P/S) of Jiangsu Recbio Technology Co is currently 190.42. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Jiangsu Recbio Technology Co stock.

The Eulerpool Quality Score for Jiangsu Recbio Technology Co is 3/10.

The ISIN of Jiangsu Recbio Technology Co is CNE1000057K9. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Jiangsu Recbio Technology Co is 2179.HK. The ticker symbol is used to trade Jiangsu Recbio Technology Co shares on the stock exchange.

Fair ValueTerminal
3.20 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
33,257.50 CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website recbio.cn
Country
Currency
CNY
Initial public offering
Mar 31, 2022
ISIN
CNE1000057K9
Market capitalization
1.64 B CNYSmall Cap
52-Week Range
PEG
0.25
P/E ratio
P/Ee 2026
-4.66
P/Ee 2027
-4.82
P/Ee 2028
-6.88
P/Se
190.42
EV/EBIT
—
P/B Ratio
2.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-44.42 %
Last updated Nov 11, 2026, 3:37 AM

Jiangsu Recbio Technology Co Peer Group

Jiangsu Recbio Technology Co Ticker

HKEX · 2179.HK

Jiangsu Recbio Technology Co FIGI

2179:HK · BBG0167SQCG4